Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cadence Design Systems Inc (CDNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Cadence Design Systems Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Cadence Design Systems Inc trades at $385.6 (market cap $105.96B). The key difference: Cadence Design Systems Inc is far larger — about 128.3× Amphastar Pharmaceuticals Inc's market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | CDNS | |
|---|---|---|
Market Cap | $826.08M | $105.96B |
Sector | Health | Technology |
52-Week High | $30.81 | $416.39 |
52-Week Low | $16.87 | $265.66 |
Enterprise Value | $1.22B | $107.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Cadence Design Systems (CDNS) trades at $384.17, down 0.46% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent revenue growth from $3.6B in 2022 to $5.3B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 83.87% buy ratings and a $395.88 consensus price target, representing 3% upside potential.
The outlook for CDNS remains favorable given its strategic position in semiconductor design software and AI-driven demand, though elevated valuation ratios (P/E 89.55, P/S 18.99) warrant caution. Key risks include semiconductor cycle volatility and competitive pressures, but strong cash flow generation and institutional support provide stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →
